HCLTECH
16.1.2023 13:14:41 CET | Business Wire | Press release
HCLTech, a leading global technology company, is joining governments, businesses and civil society from across the world at the World Economic Forum (WEF) 2023 in Davos to facilitate dialogue and collaboration for a sustainable planet and inclusive growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005173/en/
HCLTech pavilion at Promenade66, Davos (Photo: Business Wire)
HCLTech is proud of its long-standing strategic partnership with the WEF. The HCLTech Pavilion at WEF 2023 showcases the company’s new brand identity and purpose of bringing together the best of technology and people to supercharge progress for clients, its people, communities and the planet.
Located at Promenade 66, 7270 Davos Platz, the HCLTech Pavilion is fully powered by green energy, underscoring the company’s commitment to a sustainable planet.
As part of HCLTech’s focus on diversity and gender equality, the company is hosting the UN Women’s Gender Equality Hub at its Pavilion. The Hub will feature daily video check-ins, pop-up panel discussions and fireside chats.
HCLTech’s leadership team will join and host global leaders at WEF in thought-provoking sessions around the Annual Meeting’s theme of “Cooperation in a Fragmented World” and discuss solutions to address the diverse crises facing the world.
Roshni Nadar Malhotra, Chairperson, HCLTech will join former U.S. Vice President Al Gore and other distinguished leaders at “Leading the Charge through Earth’s New Normal” - a session to discuss transformative solutions and global collaboration to build a more inclusive, prosperous and sustainable future. She will also join “The Aquapreneur Revolution” - a session hosted by Emma Benameur, Head of Impact and Engagement and Member of the WEF Executive Committee to announce the winners of The Global Freshwater Innovation Challenge under HCL Group and UpLink’s quest to find innovative solutions for freshwater conservation.
C Vijayakumar, CEO & Managing Director, HCLTech will share his vision at “Preparing One Billion People for Tomorrow’s Economy” - a session to discuss critical interventions needed to skill one billion people by 2030 in a world being rapidly transformed by technology. He will be joined by Saadia Zahidi, Managing Director, WEF and business leaders from Merck, Manpower Group and UBA Group.
In addition, Santhosh Jayaram, Global Head of Sustainability, HCLTech will spearhead the “Sustainability Dialogues with HCLTech” - a series of sessions with industry-leading business and thought leaders to engage in an open dialogue, focused on the most pressing agendas and topics around sustainability.
Srinivasan Seshadri, Corporate Vice President and Global Head of Financial Services, HCLTech will be part of “Operating Models in the Wake of Deglobalization” - a session on the growing need of businesses for innovative models to insulate them from the growing volatility in the global environment.
HCLTech CMO Jill Kouri will speak at “Generation Equality Pop Up, Role of Women in Climate Action” - a session that will include Kate Behncken, Corporate Vice President, Microsoft Philanthropies and Caitlin Kraft Buchman, Founder, CEO, Women@TheTable.
To learn more about HCLTech@WEF 2023 visit https://www.hcltech.com/world-economic-forum.
About HCLTech
HCLTech is a global technology company, home to 222,000+ people across 60 countries, delivering industry-leading capabilities centered around digital, engineering and cloud, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending December, 2022 totaled $12.3 billion. To learn how we can supercharge progress for you, visit hcltech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005173/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom